PathAI

About PathAI

Products by PathAI

All products by PathAI reviewed by our AI panel of experts.

PathAIAI Healthcare

AI-powered pathology for faster, more accurate disease diagnosis

Free7.9/10

How Our Review Panel Scores PathAI

Six independent reviewer personalities assessed PathAI's product on their own terms. They disagreed by 2.4 points — The Finance Lead was the hardest to convince, The Domain Strategist the most positive.

Averaged across 1 reviewed product in our catalog. Scores are out of 10.

Competitive Landscape

Who PathAI competes with, and how they differ.

Paige.ai7.9/10

Paige focuses on FDA-cleared diagnostic AI models for specific cancers (e.g. prostate, breast) sold directly to pathology labs -- a narrower diagnostic-model line than PathAI's combined biopharma biomarker/clinical-trial services and open AISight image-management platform that hosts third-party algorithms.

1 product reviewed on TopReviewed

Lunit Inc.7.9/10

Lunit is a Seoul-based, publicly traded (KOSDAQ) company spanning both radiology (chest X-ray and mammography triage) and pathology (Lunit SCOPE biomarker quantification), giving it a broader cross-modality imaging footprint than PathAI's pathology-only focus.

1 product reviewed on TopReviewed

P

Proscia

Proscia's Concentriq platform is primarily an image-management and workflow system that labs and pharma license to run their own or third-party AI algorithms on -- competing with PathAI's AISight IMS layer more directly than with PathAI's own diagnostic and biomarker AI models.

I

Ibex Medical Analytics

Ibex concentrates on live clinical deployment of cancer-detection algorithms (breast, prostate, gastric) sold directly to pathology labs, with a smaller footprint in the biopharma clinical-trial and companion-diagnostic biomarker work that makes up a larger share of PathAI's business.

Company Timeline

Key milestones in PathAI's history, with sources.

1. May 7, 2026Acquisition

   Roche agrees to acquire PathAI for up to $1.05B

   Roche entered a definitive merger agreement to acquire PathAI for $750 million upfront plus up to $300 million in milestone payments. Subject to closing (expected H2 2026), PathAI becomes part of Roche's Diagnostics division; CEO Andy Beck remains in place through the announcement. The deal builds on the companies' 2021 and 2024 partnerships.

   roche.com
2. Mar 3, 2026Milestone

   FDA grants Breakthrough Device Designation to PathAssist Derm

   The FDA granted Breakthrough Device Designation to PathAssist Derm, an AI tool assisting pathologists reviewing digital whole-slide images of skin lesions; the tool had been commercially available since February 2025. No PathAssist Derm-specific accuracy figures were published alongside the designation.

   medicaldevice-network.com
3. Dec 9, 2025Milestone

   FDA qualifies AIM-MASH AI Assist as first AI-powered pathology drug-development tool

   The FDA qualified PathAI's AIM-MASH AI Assist through its Drug Development Tool Biomarker Qualification Program for use in MASH clinical trials (enrollment and endpoint assessment) -- the first AI-powered pathology tool so qualified, following an earlier 2025 EMA CHMP qualification. The supporting validation data was published in a peer-reviewed Nature Medicine (2025) study, per independent trade coverage; PathAI states the tool is not for diagnostic use.

   hitconsultant.net
4. Jun 26, 2025Milestone

   FDA clears AISight Dx digital pathology platform for primary diagnosis (K243391)

   The FDA granted 510(k) clearance (K243391) to PathAI's AISight Dx image-management platform for primary diagnosis in clinical settings, with an authorized Predetermined Change Control Plan -- the first digital pathology image-management system with PCCP authorization.

   accessdata.fda.gov
5. Feb 13, 2024Partnership

   Expanded exclusive partnership with Roche Tissue Diagnostics for companion diagnostics

   PathAI and Roche Tissue Diagnostics (RTD) expanded their 2021 collaboration: RTD agreed to work with PathAI as its sole external algorithm-development partner for AI-powered companion diagnostics for a pre-specified term, while PathAI retained the right to develop algorithms outside that space.

   prnewswire.com
6. Jun 22, 2022Milestone

   Co-founder & CTO Aditya Khosla departs to lead engineering at Iterative Scopes

   Aditya Khosla, PathAI's co-founder and CTO since 2016, left to become CTO of Iterative Scopes, a separate Cambridge, MA AI healthcare startup, while remaining a PathAI advisor. Andy Beck continued as CEO.

   tissuepathology.com
7. Oct 15, 2021Partnership

   Collaboration announced with Roche for AI-powered companion diagnostics

   Roche and PathAI announced a collaboration embedding PathAI's image-analysis algorithms in Roche's NAVIFY Digital Pathology software, initially distributing research-use-only algorithms across multiple cancer types to support companion diagnostics and drug development.

   roche.com
8. May 18, 2021Funding

   Series C -- $165M co-led by D1 Capital Partners and Kaiser Permanente

   PathAI closed a $165 million Series C round co-led by D1 Capital Partners and Kaiser Permanente, with participation from General Atlantic, Tiger Global, 8VC and strategic investors including Bristol-Myers Squibb, Labcorp and Merck's Global Health Innovation Fund.

   prnewswire.com
9. Apr 17, 2019Funding

   Series B -- $60M led by General Atlantic

   PathAI closed a $60 million Series B round led by General Atlantic, with continued participation from General Catalyst.

   generalatlantic.com
10. Nov 3, 2017Funding

    Series A -- $11M led by General Catalyst Partners

    PathAI raised an $11 million Series A round led by General Catalyst Partners, with participation from Pillar Companies, Refactor Capital, 8VC, Danhua Capital and KdT Ventures, bringing total funding to about $15M at the time.

    tissuepathology.com
11. 2016Founded

    PathAI founded by Andy Beck and Aditya Khosla

    Andrew (Andy) Beck, MD, PhD, and Aditya Khosla, PhD, co-founded PathAI in Massachusetts to apply machine learning to pathology image analysis for diagnostics and drug development.

    tissuepathology.com